Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer

Table 1 Patient characteristics

	all	TTF1 +	TTF1 -	p-value
Entire population	221	183/221 (82.8%)	38/221 (17.2%)
Age (mean ± SD)	64.7 ± 10.2	64.0 ± 10.2	68.1 ± 9.6	0.023*
Female n (%)	76/221 (34.4)	63/183 (34.4%)	13/38 (34.2%)	1.000**
Male n (%)	145/221 (66.6)	120/183 (65.6%)	25/38 (65.8%)	1.000**
Stage IIIA n (%)	21/221 (9.5)	16/183 (8.7%)	5/38 (13.2%)
Stage IIIB n (%)	64/221 (29.0)	56/183 (30.6%)	8/38 (21.0%)
Stage IV n (%)	136/221 (61.5)	111/183 (60.7%)	25/38 (65.8%)	0.412**

Overview of the proportion of patients with TTF1-positive and TTF1-negative SCLC in the entire patient population and in the different stage groups.
*Student’s T-Test.
**Chi-Square Test.

ISSN: 1746-1596